glycyl-leucyl-phenylalanine: an immunostimulatory peptide; RN given refer to all (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 128287 |
| CHEMBL ID | 209670 |
| CHEBI ID | 163814 |
| SCHEMBL ID | 4281374 |
| MeSH ID | M0173039 |
| Synonym |
|---|
| glycyl-leucyl-phenylalanine |
| bdbm50188525 |
| (2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]amino]-3-phenylpropanoic acid |
| CHEBI:163814 |
| gly-leu-phe |
| 103213-38-3 |
| CHEMBL209670 , |
| l-phenylalanine, n-(n-glycyl-l-leucyl)- |
| l-gly-l-leu-l-phe |
| SCHEMBL4281374 |
| h-gly-leu-phe-oh |
| (s)-2-((s)-2-(2-aminoacetamido)-4-methylpentanamido)-3-phenylpropanoic acid |
| mfcd00057838 |
| glycyl-l-leucyl-l-phenylalanine |
| (2s)-2-[[(2s)-2-[(2-azaniumylacetyl)amino]-4-methylpentanoyl]amino]-3-phenylpropanoate |
| n-{2-[(2-amino-1-hydroxyethylidene)amino]-1-hydroxy-4-methylpentylidene}phenylalanine |
| DTXSID60908255 |
| Class | Description |
|---|---|
| oligopeptide | A peptide containing a relatively small number of amino acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Solute carrier family 15 member 1 | Homo sapiens (human) | IC50 (µMol) | 980.0000 | 0.1800 | 0.1900 | 0.2000 | AID266249 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 980.0000 | 0.0002 | 0.6603 | 10.0000 | AID266249 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| monoatomic ion transport | Solute carrier family 15 member 1 | Homo sapiens (human) |
| protein transport | Solute carrier family 15 member 1 | Homo sapiens (human) |
| peptide transport | Solute carrier family 15 member 1 | Homo sapiens (human) |
| dipeptide import across plasma membrane | Solute carrier family 15 member 1 | Homo sapiens (human) |
| tripeptide import across plasma membrane | Solute carrier family 15 member 1 | Homo sapiens (human) |
| proton transmembrane transport | Solute carrier family 15 member 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| proton-dependent oligopeptide secondary active transmembrane transporter activity | Solute carrier family 15 member 1 | Homo sapiens (human) |
| peptide:proton symporter activity | Solute carrier family 15 member 1 | Homo sapiens (human) |
| tripeptide transmembrane transporter activity | Solute carrier family 15 member 1 | Homo sapiens (human) |
| dipeptide transmembrane transporter activity | Solute carrier family 15 member 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Solute carrier family 15 member 1 | Homo sapiens (human) |
| brush border | Solute carrier family 15 member 1 | Homo sapiens (human) |
| membrane | Solute carrier family 15 member 1 | Homo sapiens (human) |
| apical plasma membrane | Solute carrier family 15 member 1 | Homo sapiens (human) |
| plasma membrane | Solute carrier family 15 member 1 | Homo sapiens (human) |
| apical plasma membrane | Solute carrier family 15 member 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID266248 | Ratio of %GSmax to EC50 for human PEPT1 activation | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. |
| AID266246 | Activation of human PEPT1 expressed in MDCK cells | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. |
| AID266249 | Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. |
| AID266247 | Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||